Corporate
Almirall announces the appointment of Eduardo Sanchiz as new CEO as of July 1st 2011
Barcelona, 17th March 2011.– Almirall, the international pharmaceutical company based in Spain, announced that in view of the increasing complexity of the business, Jorge Gallardo has proposed to the Board the separation of the Chairman and CEO roles. The Board has responded by selecting Eduardo Sanchiz as the new CEO.
Jorge Gallardo in his role of Executive Chairman will continue to work with the Board and the CEO, concentrating on strategic priorities and related actions to persist in building up Almirall into a leading global healthcare corporation.
Jorge Gallardo can look back on a successful 46 year career in the pharmaceutical industry. In 1965, after obtaining his doctorate in Industrial Engineering he started work at Almirall heading different areas over the years. In 1997 he was appointed CEO, and Chairman and CEO in 2001.
Eduardo Sanchiz was born in 1956, obtained a degree in Economics and Business Administration and later an MBA. In 1982 he began his career in Eli Lilly where he remained for 22 years gaining experience in Finance, Sales Management, Marketing, Business Development and General Management. In 2004 he started at Almirall as Chief Executive Corporate Development and Finance.
The Board has full confidence in Eduardo Sanchiz’s global leadership capabilities based on his experience, his knowledge of the industry and his ability to provide direction and align and engage people. These skills will be crucial for achieving Almirall’s goals.
Eduardo Sanchiz will take over the CEO’s responsibilities as of July 1st 2011.
About Almirall
Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, Spain, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing. Almirall focuses its research resources on therapeutic areas related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and other dermatological conditions. Almirall’s products are currently present in over 70 countries while it has direct presence in Europe and Latin America through 12 affiliates.
For further information please visit the website at: www.almirall.com
Press release